DUBLIN, April 23, 2014 /PRNewswire/ --
Dublin -
Research and Markets
(http://www.researchandmarkets.com/research/9kz4vm/the_overview_of)
has announced the addition of the "The Overview of Japanese CRO
Market" report to their offering.
(Logo:
http://photos.prnewswire.com/prnh/20130307/600769 )
This report presents an overview of the CRO (contract research
organization) market in Japan. By
reading this report, end-users will gain an overall picture of the
Japanese CRO market, including the market size trend, major CRO
players, and competitive difference between local and global
CROs.
Japanese CRO market has been expanding for the past 10 years, and
it reached a total size of ¥133 billion in 2012. When broken down
by service, monitoring accounted for 54% of total and followed by
data management and statistical analysis with 23%.
Japanese pharmaceutical firms traditionally used to have a strong
tendency to do clinical trial works in-house. However, with
large-scale new drug development becoming difficult in recent
years, keeping many staff in clinical development area has become
an operational risk. As a result, it has been now common to see
that both foreign and domestic firms in Japan utilize CROs for their clinical
development works.
While there are approximately 50 CROs in this market, the largest 4
companies, EPS, CMIC, Quintiles, and Parexel, are dominating the
market, and the rest of firms have faced stagnation or decreasing
number of projects. There are several factors behind this.
- In recent years, pharmaceutical firms have started to work with
a CRO who has capability to offer full service with enough
resources.
- Not only foreign pharmaceutical companies but also domestic
companies now have selected specific CROs as preferred
vendors.
- Furthermore, in recent years, companies have started to look
for exclusive partnerships model with CROs, such as Pfizer and
Parexel+Icon, Eisai and Quintiles, etc., to seek more benefit in
economics and shorter time.
Clearly, Japanese CROs get local projects, and global CROs take
global studies. Japanese CROs leverage their low cost and ability
to interact with clients in Japanese, to get domestic studies. On
the other hand, global CROs, takes advantage of their capability in
international studies and global reach.
In this situation, large Japanese CROs have been trying to expand
the operation in Asia, to get
multinational studies. Also, some CROs such as CMIC are moving into
horizontal business expansion; CSO, CMO etc., positioning
themselves as one-stop service provider for entire pharmaceutical
business.
Large foreign-owned CROs are strengthening regional capability,
investing facilities and resources in functional services such as
central laboratories, imaging, clinical supply and so on, to take
domestic projects away from local CROs.
Demand for outsourcing clinical development works has remained
strong. Therefore, Japanese CRO market will likely continue to grow
for a while. More concentration into the top 4 companies is also
expected in the near future. The environment surrounding small- and
mid-sized CROs will become difficult more and more over the time.
The key to success for them to survive this tough market would be
securing quality operational staff that can satisfy clients'
needs.
Key Topics Covered:
1. Summary
2. Definition of CRO market
3. Market size
4. Rational necessity for pharma to use CRO
5. Industry Association
6. Major CRO companies
7. Market trend
8. Future outlook
Companies Mentioned:
- Cimic
- EPS
- Mediscience Planning
- Parexel
- Quintiles
For more information visit
http://www.researchandmarkets.com/research/9kz4vm/the_overview_of
Media Contact: Laura Wood ,
+353-1-481-1716, press@researchandmarkets.net